Evidence map›Paper›PMID 34196100›Full record

ArticleJournal of biomedical materials research. Part A2021

Superporous agarose scaffolds for encapsulation of adult human islets and human stem-cell-derived β cells for intravascular bioartificial pancreas applications.

Rebecca Shaheen, Rachel E Gurlin, Rebecca Gologorsky, Charles Blaha, Pujita Munnangi, Ana Santandreu, Alonso Torres, Phichitpol Carnese, Gopika G Nair, Gregory Szot and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biomedical materials research. Part A, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Rebecca ShaheenDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA.ORCID 0000-0002-5121-8558
Rachel E GurlinDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA.ORCID 0000-0002-6139-4328
Rebecca GologorskyDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA.
Charles BlahaDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA.
Pujita MunnangiDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA.
Ana SantandreuDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA.
Alonso TorresDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA.
Phichitpol CarneseDiabetes Center, Department of Medicine, University of California, San Francisco, California, USA.
Gopika G NairDiabetes Center, Department of Medicine, University of California, San Francisco, California, USA.
Gregory SzotDiabetes Center, Department of Medicine, University of California, San Francisco, California, USA.
William H FissellSilicon Kidney, San Francisco, California, USA.
Matthias HebrokDiabetes Center, Department of Medicine, University of California, San Francisco, California, USA.
Shuvo RoyDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA.
University of California, San Francisco · USVanderbilt University Medical Center · US

Funding

Building an Implantable Artificial KidneyU01EB021214 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FISSELL, WILLIAM H, ROY, SHUVO · 2015 to 2018
$6.0M
Implantable Bio-Artificial Pancreas (iBAP)U01EB025136 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROY, SHUVO · 2017 to 2021
$3.2M
An intravascular Bioartificial Pancreas (iBAP)R44DK104299 · NIDDK · SILICON KIDNEY, LLC · PI BLAHA, CHARLES · 2018 to 2025
$2.5M
R25EB023856 Supplement LeeYM P0546225R25EB023856 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEE, HANMIN, ROY, SHUVO · 2017 to 2021
$698k
Breakthrough T1D 3-SRA-2015-37-Q-RNIBIB NIH HHS R25 EB023856NIBIB NIH HHS U01 EB021214NIBIB NIH HHS U01 EB025136NIBIB NIH HHS U01EB025136NIDDK NIH HHS R44 DK104299NIH HHS R44DK104299
6 · The paper itself

Abstract

Type 1 diabetic patients with severe hypoglycemia unawareness have benefitted from cellular therapies, such as pancreas or islet transplantation; however, donor shortage and the need for immunosuppression limits widespread clinical application. We previously developed an intravascular bioartificial pancreas (iBAP) using silicon nanopore membranes (SNM) for immunoprotection. To ensure ample nutrient delivery, the iBAP will need a cell scaffold with high hydraulic permeability to provide mechanical support and maintain islet viability and function. Here, we examine the feasibility of superporous agarose (SPA) as a potential cell scaffold in the iBAP. SPA exhibits 66-fold greater hydraulic permeability than the SNM along with a short (<10 μm) diffusion distance to the nearest islet. SPA also supports short-term functionality of both encapsulated human islets and stem-cell-derived enriched β-clusters in a convection-based system, demonstrated by high viability (>95%) and biphasic insulin responses to dynamic glucose stimulus. These findings suggest that the SPA scaffold will not limit nutrient delivery in a convection-based bioartificial pancreas and merits continued investigation.

Indexed as

Insulin-Secreting CellsIslets of LangerhansPancreas, ArtificialTissue ScaffoldsAdultDiabetes Mellitus, Type 1GlucoseGraft vs Host DiseaseHumansIslets of Langerhans TransplantationMembranes, ArtificialNanoporesSepharoseSiliconStem Cell TransplantationGlucoseMembranes, ArtificialSepharoseSiliconhydraulic permeabilitymacroporous scaffoldsstem cell-derived beta cellstype 1 diabetes (T1D)

Identifiers

PMID34196100
PMCPMC13653688
OpenAlexW3174858673

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.